R&D

    Therapeutics

    Microbiome Therapeutics Pipeline - Inflammatory Diseases

    Pipeline
    Indication
    Discovery
    Preclinical
    Clinical Development
    Phase1
    Phase2
    Phase3
    LABTHERA-005
    Inflammatory Diseases
    Chronic cholangitis is a persistent inflammatory disease of the biliary tract, including the gallbladder and bile ducts, often resulting from recurrent acute cholecystitis or bile duct obstruction caused by gallstones, which disrupts bile flow and promotes bacterial infection.
    The gut microbiome is closely linked to the pathogenesis of chronic cholangitis. Microbiome dysbiosis has been shown to exacerbate inflammatory responses by increasing pro-inflammatory cytokine secretion and intestinal permeability, allowing microbial components and toxins to translocate into the bloodstream and trigger inflammation in the liver and biliary system.
    ATOGEN is developing differentiated microbiome-based therapeutics for chronic cholangitis by identifying proprietary strains from its internal strain library that inhibit gallstone formation and modulate inflammatory pathways. Microbiome-based therapies offer the potential for safe use as monotherapy or in combination with existing treatments, providing a multi-mechanistic, disease-relevant approach to chronic cholangitis without the burden of systemic side effects.